FWN-42695-64141
4 vaccinations
1 coded response
4 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 870 / NM
- Registered
- 2023-04-11
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-17
Dose 1 — Pfizer-BioNTech
-
2021-04-06
Dose 2 — Pfizer-BioNTech
-
2021-11-08
Dose 3 — Pfizer-BioNTech
-
2023-04-10
Dose 4 — Pfizer-BioNTech
-
2023-04-11
Registered in v-safe
-
2023-04-11
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2023-04-12
-
2023-04-13
Survey response — days 1–6 daily, dose 4MedDRA: Salivary gland disorder, Salivary gland enlargement — Feeling: Fair · Muscle or body achesMedDRA releases: 2024-11
- 2023-04-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-17 | Pfizer-BioNTech | No |
| 2 | 2021-04-06 | Pfizer-BioNTech | No |
| 3 | 2021-11-08 | Pfizer-BioNTech | No |
| 4 | 2023-04-10 | Pfizer-BioNTech | No |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Salivary gland disorder | · | · | ✓ |
| SRO | Salivary gland enlargement | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release